‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable

CDER Manual of Policy and Procedures describes specific actions FDA review staff will take once a product has received “breakthrough therapy” designation, with an emphasis on more meetings, more frequently.